<DOC>
	<DOCNO>NCT02125240</DOCNO>
	<brief_summary>The purpose study compare 2 year disease-free survival ( DFS ) Icotinib placebo treatment patient EGFR mutation-positive II-IIIA lung adenocarcinoma .</brief_summary>
	<brief_title>Icotinib Versus Placebo Adjuvant Therapy EGFR-mutant Lung Adenocarcinoma</brief_title>
	<detailed_description>This study design compare 2 year disease-free survival ( DFS ) Icotinib placebo treatment patient EGFR mutation-positive II-IIIA lung adenocarcinoma . Primary Outcome Measure : Disease-free survival Icotinib group placebo group . Secondary Outcome Measures : Overall survival Icotinib group placebo group . Lung cancer symptom health-related quality life ( HRQoL ) . Number participant adverse event .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Pathologically confirm lung adenocarcinoma surgical resection Stage IIIIIA disease accord 7th edition TNM stag Patients must harbor sensitive EGFR gene mutation ( 19/21 ) Received four cycle platinumbased adjuvant chemotherapy.There many different kind chemotherapy regimen include vinorelbine , gemcitabine , docetaxel , paclitaxel , pemetrexed plus cisplatin carboplatin.The first cycle chemotherapy cisplatin dose 75 mg / m2 ± 10 % carboplatin AUC = 5 ± 10 % calculate dose chemotherapy Previous systemic antitumor therapy , include chemotherapy target therapy ( Including limit monoclonal antibody , small molecule tyrosine kinase inhibitor , etc Presence metastatic disease Other coexist malignancy malignancy diagnose within last 5 year exception basal cell carcinoma cervical cancer situ Any unresolved chronic toxicity previous anticancer therapy Received antitumor radiation therapy ( except stage IIIA N2 patient receive adjuvant radiotherapy surgery )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>